Vertex Pharmaceuticals (NASDAQ: VRTX) and its partner, CRISPR Therapeutics (NASDAQ: CRSP), have achieved significant progress with their drug targeting rare blood diseases beta thalassemia and sickle cell disease. But the big biotech isn’t limiting its options in developing gene-editing therapies. In this Motley Fool Live video recorded on Oct. 27, 2021, Motley Fool contributors Keith Speights and Brian Orelli, PhD discuss why Vertex is striking another gene-editing deal with a company not named CRISPR Therapeutics.